Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations

References

• Abrol S, Trehan A, Katare OP. (2004). Formulation, characterization, and in vitro evaluation of silymarin-loaded lipid microspheres. Drug Deliv 11:185–91
   PubMed Web of Science ®Google Scholar
• Alex A, Paul W, Chacko AJ, et al. (2011). Enhanced delivery of lopinavir to the CNS using compritol-based solid lipid nanoparticles. Ther Deliv 2:25–35
   PubMedGoogle Scholar
• Antuono P, Beyer J. (1999). The burden of dementia: a medical and research perspective. Theor Med Bioeth 20:3–13
   PubMed Web of Science ®Google Scholar
• Behan N, Birkinshaw C. (2001). Preparation of poly (butyl cyanoacrylate) nanoparticles by aqueous dispersion polymerisation in the presence of insulin. Macromol Rapid Comm 22:41–3
   Web of Science ®Google Scholar
• Chopra K, Misra S, Kuhad A. (2011a). Neurobiological aspects of Alzheimer's disease. Expert OpinTher Targets 15:535–55
   PubMed Web of Science ®Google Scholar
• Chopra K, Misra S, Kuhad A. (2011b). Current perspectives on pharmacotherapy of Alzheimer's disease. Expert Opin Pharmacother 12:335–50
   PubMed Web of Science ®Google Scholar
• Cirrito JR, Holtzman DH. (2003). Amyloid β and Alzheimer's disease therapeutics: the devil may be in details. J Clin Invest 112:321–23
   PubMed Web of Science ®Google Scholar
• Corrigan OI, Li X. (2009). Quantifying drug release from PLGA nanoparticulates. Euro J Pharm Sci 37:477–85
   PubMed Web of Science ®Google Scholar
• Feng S, Huang G. (2001). Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Release 71:53–69
   PubMed Web of Science ®Google Scholar
• Gao S, Hendrie HC, Hall KS, Hui S. (1998). The relationship between age, sex, and the incidence of dementia and Alzheimer's disease: a meta-analysis. Arch Gen Psychiatry 55:809–15
   PubMed Web of Science ®Google Scholar
• Genta M, Costantini A, Asti B, Conti L. (1998). Influence of glutaraldehyde on drug release and mucoadhesive properties of chitosan microspheres. Carbohydr Polym 36:81–8
   Web of Science ®Google Scholar
• Guttman R, Altman RD, Nielsen NH. (1999). Alzheimer disease: report of the council on scientific affairs. Arch Family Med. 8:347–53
   PubMedGoogle Scholar
• Handy RD, Henry TB, Scown TM, et al. (2008). Manufactured nanoparticles: their uptake and effects on fish mechanistic analysis. Ecotoxicology 17:396–409
   PubMed Web of Science ®Google Scholar
• Hernandez CM, Kayed R, Zheng H, et al. (2013). Loss of alpha 7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 30:2442–53
   Web of Science ®Google Scholar
• Hu Y, Jiang X, Ding Y, et al. (2003). Preparation and drug release behaviors of nimodipine-loaded poly (caprolactone) poly (ethylene oxide) polylactide amphiphilic copolymer nanoparticles. Biomaterials 24:2395–404
   PubMed Web of Science ®Google Scholar
• Katare OP, Raza K, Singh B, Dogra S. (2010). Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian J Dermatol Venereol Leprol 76:612–21
   PubMed Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, Kakkar V. (2008). Potential of solid lipid nanoparticles in brain targeting. J Control Release 127:97–109
   PubMed Web of Science ®Google Scholar
• Kim H, Kim Y, Lee J. (2013). Liposomal formulations for enhanced lymphatic drug delivery. Asian J Pharm Sci 8:96–103
   Google Scholar
• Leon J, Cheng CK, Neumann PJ. (1998). Alzheimer's disease care: costs and potential savings. Health Aff (Millwood). 17:206–16
   PubMed Web of Science ®Google Scholar
• Lockman PR, Koziara JM, Mumper RJ, Allen D.D. (2004). Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 12:635–41
   PubMed Web of Science ®Google Scholar
• Maelicke A, Albuquerque EX. (2000). Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393:165–70
   PubMed Web of Science ®Google Scholar
• Maelicke A, Samochocki M, Jostock R, et al. (2001). Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry 49:279–88
   PubMed Web of Science ®Google Scholar
• Mannens GSJ, Snel CAW, Hendrickx J, et al. (2002). The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 30:553–63
   PubMed Web of Science ®Google Scholar
• Misra S, Tiwari V, Kuhad A, Chopra K. (2011). Modulation of nitrergic pathway by sesamol prevents cognitive deficits and associated biochemical alterations in intracerebroventricular streptozotocin administered rats. Eur J Pharmacol 659:177–86
   PubMed Web of Science ®Google Scholar
• Morris RGM, Garrud P, Rawlins JNP, O'Keefe J. (1982). Place navigation impaired in rats with hippocampal lesions. Nature 297:681–3
   PubMed Web of Science ®Google Scholar
• Muller RH, Schwarz C, Mehnert W, Lucks JS. (1993). Production of solid lipid nanoparticles for controlled drug delivery. Proc Int Symp Control Rel Bioact Mater 20:480–7
   Google Scholar
• Patel KB, Patel AV, Patel VJ, et al. (2010). Quantitative determination of galantamine hydrobromide in pharmaceutical dosage form by RP- high performance liquid chromatography. J Chem Pharm Res 2:36–43
   Google Scholar
• Service RF. (2003). American Chemical Society meeting. Nanomaterials show signs of toxicity. Science (NY) 300:243–50
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Wessel T, Yuan W. (2000). Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54:2261–8
   PubMed Web of Science ®Google Scholar
• Raza K, Katare OP, Setia A, et al. (2013a). Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J Microencapsul 30:225–36
   PubMed Web of Science ®Google Scholar
• Raza K, Singh B, Singal P, et al. (2013b). Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloid Surface B 105:67–74
   PubMed Web of Science ®Google Scholar
• Sehra S, Dhake AS. (2005). Formulation and evaluation of sustained release microspheres of poly-lactide-co-glycolide containing tamoxifen citrate. J Microencaps 22:521–8
   PubMed Web of Science ®Google Scholar
• Shi F, Zhao JH, Liu Y, et al. (2012). Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil. Int J Nanomedicine 7:2033–43
   PubMed Web of Science ®Google Scholar
• Singh J, Garg T, Rath G, Goyal AK. (2015). Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis – a critical review. Drug Deliv 11:1–23
   Google Scholar
• Sruthi N, Joe F, Kumar S. (2015). Formulation and evaluation of galantamine nanoparticles for neurological disorders. IJPCBS 5:63–70
   Google Scholar
• Takata K, Kitamura Y, Saeki M, et al. (2010). Galantamine-induced amyloid-beta clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 285:40180–91
   PubMed Web of Science ®Google Scholar
• Wang DL, Ling ZQ, Cao FY, et al. (2004). Melatonin attenuates isoproterenol induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J Pineal Res 37:11–16
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Lilienfeld S, Gaens E. (2000). Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine international-1 study group. BMJ 321:1445–9
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi M, et al. (2008). Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 1200:159–68
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B. (2001). Health economical aspects of Alzheimer's disease and its treatment. Psychogeriatrics 1:189–93
   Google Scholar
• Wyss R. (1990). Chromatography of retinoids. J Chromatogr B Biomed Sci Appl 531:481–508
   Web of Science ®Google Scholar
• Yanagida T, Takeuchi H, Kitamura Y, et al. (2008). Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model. Neurosci Res 62:254–61
   PubMed Web of Science ®Google Scholar